Introduction: 
The urachus is an embryologic remnant which is formed from the obliteration of the allantois. Urachal abnormalities are caused when defective obliteration of the urachus happens. They are an infrequent condition. 
Clinical case: 
We present the case of a 38-year-old male patient, with no previous medical history, evaluated in the urology consultation due to dysuria and the presence of whitish exudate after urination for years of evolution, without any other symptom. 
The physical examination is normal, with negative urethral exudate and negative urine culture. A cystoscopy is requested: a dome image suspicious of urachal pathology is observed. A CT scan was performed that showed a 19x24x45 cm tubular structure with a cystic appearance, compliant with a urachal diverticulum. After these findings, the case was discussed in a clinical session and a systematic search of the literature was carried out to determine the attitude to follow. 
There is no clear indication in the literature about the management of urchal pathology, being able to opt for surgery o conservative management. Given the persistent symptoms and despite the low risk of urachal cancer (incidence of 0.18 per 100,000), we performed a laparoscopic resection The histological analysis report a mucinous cystic tumor with low potential for malignancy. Urooncological committee decided very close monitoring, with imaging test. 
Conclusion: 
Despite the low risk of urachal cancer in adults, we must consider the possibility of resection or close control of it, given the possibility of malignancy.

URACHAL REMNANT, risk of malignancy. A CASE REPORT.

For 2021, our focus remains: turning new data into your daily practice. The programme will consist of state-of-the-art lectures, case discussions and panel debates. Our faculty is a group of international & multidisciplinary experts.

We will take you on our journey to Ghent and beyond. Prior the congress, we send out case challenges, where you can compare your opinion with peers & experts. These cases will be part of the Global Congresses on Prostate & Bladder Cancer programme during the congress days (12 & 13 October for PROSCA and 14 & 15 October for BLADDR). After these days, you will be updated on prostate & bladder cancer management.